One year after the commercial launch of the MiniMed 670G system, another technological breakthrough promises to rock the diabetes world. On May 21, Boston-based Beta Bionics Inc announced that it received FDA approval to begin recruitment for home-use studies testing its version of an “artificial pancreas”. Trials for the iLet ™ bionic pancreas start in the Bay Area THIS MONTH. Even more good news for the Carb DM community: Dr. Ed Damiano, inventor of the iLet™, is coming to the Bay Area and talking about the iLet™ with Carb DM! Don’t miss this exciting and informative event happening on June 13. Don’t know anything about the iLet™? Read the primer* below to get yourself up to speed.
The iLet ™ is the brainchild of Dr. Ed Damiano, a professor of biomedical engineering at Boston University. He began working on an artificial pancreas system when his son David, now 18, was diagnosed with type 1 diabetes as an infant. He and his research team at Boston University have been working on the iLet™ ever since. In 2015, Dr. Damiano founded Beta Bionics, a for-profit Massachusetts public benefit corporation in order to commercialize the iLet™. Dr. Damiano serves as Beta Bionics’ President and CEO. Investors include Eli Lilly, Zealand Pharma, and Novo Nordisk.
About the iLet™
The iLet™ bionic pancreas system automatically and autonomously manages blood sugars 24/7. Unlike the Medtronic Minimed 670G, the iLet™ is a dual-hormone system, i.e it can dispense both insulin and glucagon. The iLet™ uses clinically tested mathematical dosing algorithms developed by Dr. Damiano and his team. The algorithms calculate and command doses of insulin and/or glucagon based on CGM sensor glucose data. Moreover, the algorithms adapt in real-time to changes in insulin needs due to hormonal changes, physical activity, emotional state, etc..
We first profiled the iLet™ on the blog in early 2016. The prototype at that time consisted of two Tandem pumps, a Dexcom CGM, and an iPhone hosting the dosing algorithm. The iLet™ has come a long way since then! The current configuration consists of:
- a dual-chamber infusion pump capable
- an integrated continuous glucose monitor (CGM);
- an external, wearable device housing the dosing algorithms, with integrated touchscreen and user interface
- a custom infusion set for subcutaneous delivery of insulin alone, glucagon alone, or insulin and glucagon.
- Initialized by entering body weight only
- Does not require the patient to count carbohydrates or calculate carb-to-insulin ratios
- Does not require the patient set insulin basal rates or bolus for meals
- Works in three modes: as an insulin-only bionic pancreas, glucagon-only bionic pancreas, or a dual-hormone bionic pancreas
Want to learn more about the iLet™? Come to our Type 1 Topics event with Dr. Ed Damiano!
Jun 13, 2018
7:00 pm – 9:00 pm
Parents Place, Palo Alto
Click here to register